65results about "Agression altered materials" patented technology

A method for reversibly, or irreversibly, altering the permeability of cells, tissues or other biological barriers, to molecules to be transported into or through these materials, through the application of acoustic energy, is enhanced by applying the ultrasound in combination with devices for monitoring and / or implementing feedback controls. The acoustic energy is applied directly or indirectly to the cells or tissue whose permeability is to be altered, at a frequency and intensity appropriate to alter the permeability to achieve the desired effect, such as the transport of endogenous or exogenous molecules and / or fluid, for drug delivery, measurement of analyte, removal of fluid, alteration of cell or tissue viability or alteration of structure of materials such as kidney or gall bladder stones. In the preferred embodiment, the method includes measuring the strength of the acoustic field applied to the cell or tissue at the applied frequency or other frequencies, and using the acoustic measurement to modify continued or subsequent application of acoustic energy to the cell or tissue. In another preferred embodiment, the method further includes simultaneously, previously, or subsequently exposing the cell or tissue to the chemical or biological agent to be transported into or across the cell or tissue. In another preferred application, the method includes removing biological fluid or molecules from the cells or tissue simultaneously, previously or subsequently to the application of acoustic energy and, optionally, assaying the biological fluid or molecules.

The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.

Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location near the all-trans retinal Schiff base, e.g., to extends the duration time of the open state. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion channels or pumps or for controlling currents in a cell (e.g., in vivo or in vitro environments).

The present invention provides the use and composition of matter of angiogenic or other growth / cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.

This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and / or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and / or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and / or lens capsule.

Cancer cells can be synchronized to the G2 / M phase by delivering an anti-microtubule agent (e.g., paclitaxel or another taxane) to the cancer cells, and applying an alternating electric field with a frequency between 100 and 500 kHz to the cancer cells, wherein at least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. This synchronization can be taken advantage of by treating the cancer cells with radiation therapy after the combined action of the delivering step and the applying step has increased a proportion of cancer cells that are in the G2 / M phase. The optimal frequency and field strength will depend on the particular type of cancer cell being treated. For certain cancers, this frequency will be between 125 and 250 kHz (e.g., 200 kHz) and the field strength will be at least 1 V / cm.

This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and / or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and / or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and / or lens capsule.

Cancer treatment is provided, by irradiating an individual with a localized, high single dose or short course of doses at a primary tumor site; collecting T cells from the individual after a period of time sufficient activation of an anti-tumor response; treating the individual with an effective dose of dose of chemotherapy; and reintroducing the T cell population back to the individual.

This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion related complication by the recipient to cells in the donor blood. The invention is also directed towards a process for preventing rejection of a donor organ by a recipient comprising the steps of transfusing the recipient of the donor organ with treated platelets; and transplanting the donor organ into the recipient.

A method of inhibiting growth of, reducing or eliminating a cell population of a subject in need thereof is disclosed. The method comprises (a) thermally, mechanically and / or chemically damaging antigen-bearing cells which comprise at least one antigen characterizing cells of the cell population, with the proviso that the chemically damaging of the antigen-bearing cells is not predominantly effected using one or more antineoplastic agents, thereby generating immunogenic cells; and (b) introducing in the subject a cell aggregate which comprises the immunogenic cells and added antigen-presenting cells, thereby inducing an immune response for inhibiting growth of, reducing or eliminating the cell population of the subject.

Mammalian disorders associated with a deficiency in the cytokine interleukin-10 (IL-10) can be alleviated by stimulating in vivo secretion and / or activity of IL-10 in the patient's blood or tissues by application of external stimulus.

The invention relates to methods and compositions for treating demyelination and / or dysmyelination and / or promoting remyelination of neurons and / or preventing the development of myelin-related diseases by administering to a subject in need thereof an effective amount (either therapeutic or prophylactic) of an elemental gold crystal nanosuspension.

The invention provides a medical carbon rod which comprises a hollow rod body and medicine cores arranged in the hollow rod body, wherein the hollow rod body consists of 45%-60% of graphite powder with high wear resistance and 40%-55% of a sugar binder; the flux cores comprise a red-light flux core consisting of 45%-55% of lithium carbonate, 25%-35% of strontium carbonate, 10%-20% of potassium carbonate and 5%-10% of the sugar binder, a yellow-light flux core consisting of 45%-55% of sodium oxide, 25%-35% of sodium carbonate, 10%-20% of sodium hydroxide and 5%-10% of the sugar binder, a green-light flux core consisting of 60%-70% of copper, 25%-35% of copper oxide, and 5%-10% of the sugar binder, and a blue-light flux core consisting of 35%-45% of zinc oxide, 30%-40% of ytterbium oxide, 15%-25% of dysprosium oxide and 5%-10% of the sugar binder. According to the technical scheme, the selected compound ingredients are beneficial to a human body, are non-toxic and harmless, and are great in treatment energy.